# Actein (from Actaea racemosa / Black Cohosh)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/actein-from-actaea-racemosa-black-cohosh
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** β-D-xylopyranoside triterpene, Actein (Cimicifuga racemosa / Cimicifuga foetida), Actein (from Cimicifuga racemosa / Actaea racemosa), cycloartane glycoside actein, black cohosh actein, Cimicifuga racemosa actein, Actaea racemosa triterpene glycoside

## Overview

Actein is a cycloartane-type triterpene glycoside (β-D-xylopyranoside) from black cohosh rhizome that inhibits breast cancer cell proliferation (IC50 0.065 μM), suppresses VEGFR1 expression in endothelial cells, and modulates [NF-κB](/ingredients/condition/inflammation), Ras/Raf/MEK/ERK, and JNK signaling pathways. In murine models, oral administration at 10–15 mg/kg for 28 days significantly reduced 4T1 breast tumor volume, lung and liver metastasis, and angiogenic gene expression, while increasing peripheral blood CD4/CD8 ratios.

## Health Benefits

- **Anti-Angiogenic Activity**: Actein suppresses VEGFR1 protein expression in human microvascular endothelial cells (HMEC-1) in a concentration-dependent manner (maximal effect at 20 μM), reducing pathological blood vessel formation that supports tumor growth.
- **Breast Cancer Cell Inhibition**: Actein selectively inhibits 4T1 murine breast cancer cell proliferation at an IC50 of 0.065 μM via ³H-thymidine incorporation assays, with activity observed at concentrations below 20 μM without measurable cytotoxicity to normal cells.
- **Menopausal Symptom Relief**: As a key bioactive constituent of black cohosh extracts, actein contributes to the traditional and contemporary use of the herb for alleviating hot flushes, night sweats, and hormonal imbalances associated with menopause.
- **[Immunomodulat](/ingredients/condition/immune-support)ion**: Oral actein administration in tumor-bearing mice elevated the peripheral blood CD4/CD8 T-cell ratio, suggesting enhancement of cell-mediated immune surveillance relevant to anti-tumor defense.
- **Metastasis Suppression**: In 4T1 syngeneic mouse tumor models, actein at 10–15 mg/kg orally for 28 days reduced both lung and liver metastatic burden, correlating with downregulation of Angiopoietin-2 (Ang2) and VEGFR1 mRNA in tumor tissue.
- **Chemotherapy Synergy**: Actein has demonstrated synergistic growth inhibition of human breast cancer cells when combined with standard chemotherapeutic agents, partially mediated through intracellular calcium release and concurrent modulation of survival signaling cascades.
- **Anti-Proliferative Signaling Modulation**: Actein downregulates phosphorylation of ERK and JNK kinases in endothelial cells at 5–20 μM (p < 0.05), disrupting mitogenic signaling that drives both tumor angiogenesis and cancer cell proliferation.

## Mechanism of Action

Actein exerts its primary anti-proliferative and anti-angiogenic effects through simultaneous modulation of multiple intracellular signaling cascades: it suppresses the Ras/Raf/MEK/ERK pathway and inhibits JNK phosphorylation in endothelial cells at concentrations of 5–20 μM, reducing pro-survival and pro-migratory signaling. In breast cancer cells, actein induces intracellular calcium release and downregulates NF-κB transcriptional activity, thereby impairing [inflammatory](/ingredients/condition/inflammation) gene expression programs that support tumor survival and immune evasion. At the angiogenic level, actein concentration-dependently reduces VEGFR1 protein expression in HMEC-1 human microvascular endothelial cells and lowers mRNA levels of both VEGFR1 and Angiopoietin-2 (Ang2) within tumor microenvironments, limiting neovascularization necessary for tumor expansion. The [immunomodulatory](/ingredients/condition/immune-support) effect, evidenced by an increased CD4/CD8 ratio in vivo, suggests actein may additionally enhance adaptive immune responses through mechanisms not yet fully characterized at the molecular level.

## Clinical Summary

No human clinical trials have been conducted using isolated, purified actein as the investigational compound; therefore, no clinical efficacy, safety, or dosing conclusions can be drawn for actein specifically in human populations. Human clinical data for menopausal symptom relief derives from trials of whole black cohosh extracts (e.g., isopropanolic extract Remifemin), in which actein is one of numerous bioactive constituents and not the isolated variable. Preclinical in vivo studies in mice provide the most structured efficacy data: oral actein at 10–15 mg/kg for 28 days produced statistically significant reductions in 4T1 tumor volume and metastatic colonization of lung and liver tissue (n=6/group, box-whisker analysis), with concomitant angiogenic gene suppression. Confidence in translating these findings to human clinical benefit is low pending Phase I/II trial data; the compound's potent in vitro IC50 (0.065 μM) and oral bioavailability in rodents provide a rational basis for future clinical investigation.

## Nutritional Profile

Actein is a pure isolated bioactive compound (molecular formula C37H56O10, MW approximately 653 g/mol) and does not possess a conventional nutritional profile with macronutrients or micronutrients. As a cycloartane-type triterpene glycoside, it carries a β-D-xylopyranoside sugar moiety attached to a tetracyclic triterpene aglycone backbone, conferring amphiphilic properties that influence membrane interaction and oral absorption. In the context of whole black cohosh rhizome, the phytochemical matrix includes additional triterpene glycosides (23-epi-26-deoxyactein, cimicifugoside, cimiracemoside), isoflavones (formononetin, though disputed in some extracts), phenolic acids (caffeic acid, isoferulic acid), and alkaloids, all of which may contribute to bioavailability and synergistic activity. Oral bioavailability of actein in rats reaches a serum Cmax of approximately 2.4 μg/mL at Tmax of 6 hours following 35.7 mg/kg gavage, with metabolite contributions to observed biological effects not yet fully characterized.

## Dosage & Preparation

- **Purified Research Compound**: Used exclusively in preclinical settings; no standardized human dose established. Murine oral doses of 10–15 mg/kg/day for 28 days produced anti-tumor effects; rat pharmacokinetic dose was 35.7 mg/kg.
- **Human Dose Estimate (Allometric Scaling, Unadjusted)**: Murine 10–15 mg/kg corresponds approximately to 0.8–1.2 mg/kg in humans using standard body surface area conversion, but this has not been validated clinically.
- **Black Cohosh Standardized Extract**: The most common human-available form containing actein; extracts are typically standardized to 2.5% triterpene glycosides (as 27-deoxyactein) per European Pharmacopoeia standards. Typical commercial dose: 40–80 mg extract (equivalent to ~8–40 mg crude rhizome) twice daily.
- **Aqueous Tincture/Maceration**: Traditional preparation method involving maceration or percolation of dried black cohosh rhizome in aqueous-ethanolic solvent; actein and 26-deoxyactein co-precipitate with protoanemonin analogues. Standardization of actein content in tinctures is inconsistent.
- **Hydrodistillation Extract**: Used in phytochemical research; yields variable actein concentrations depending on rhizome quality, geographic origin, and harvest timing.
- **Timing**: Black cohosh extracts are typically taken with meals to reduce gastrointestinal discomfort; duration of use for menopausal symptoms is conventionally limited to 6 months based on regulatory guidance, though evidence for this cutoff is not definitive.

## Safety & Drug Interactions

At concentrations below 20 μM in cell-based assays, actein demonstrated no cytotoxicity as measured by MTT and trypan blue exclusion assays; however, systemic safety data in humans for isolated actein does not exist, as no human trials have been conducted. In the broader black cohosh context, the herb carries a regulatory advisory in several countries (including Germany's BfArM) recommending limiting use to 6 months due to rare reports of hepatotoxicity, though a causal relationship between black cohosh and liver injury remains debated and specific actein involvement is uncharacterized. Potential drug interactions relevant to actein-containing black cohosh extracts include additive effects with hormone therapies, cytochrome P450 3A4 substrates (black cohosh weakly inhibits CYP3A4), and theoretical potentiation of chemotherapy drugs given demonstrated synergy in preclinical models — requiring medical supervision in oncology contexts. Actein and black cohosh extracts are contraindicated or require caution in pregnancy (uterotonic historical use), active hormone-sensitive malignancies (estrogen receptor status debated), and patients with pre-existing hepatic conditions; use during lactation is not recommended due to insufficient safety data.

## Scientific Research

The current body of evidence for isolated actein is exclusively preclinical, comprising in vitro cell-based assays and in vivo murine studies, with no published human clinical trials specifically evaluating purified actein as of the available literature. In vitro work has employed standardized proliferation assays (³H-thymidine incorporation, MTT, trypan blue exclusion) across multiple cell lines including 4T1 murine breast cancer and HMEC-1 human endothelial cells, providing reproducible IC50 values and dose-response data. Animal studies utilized syngeneic 4T1 tumor implantation models with n=6 per group, oral gavage dosing (10–15 mg/kg for 28 days), and quantitative endpoints including tumor volume, metastatic nodule counts, gene expression (qPCR), and flow cytometric immune profiling, yielding statistically significant outcomes. Pharmacokinetic data from rat gavage (35.7 mg/kg) demonstrated detectable serum actein peaking at 2.4 μg/mL at 6 hours, confirming oral bioavailability, but human PK and dose translation remain unvalidated, placing overall evidence strength firmly at the preliminary preclinical stage.

## Historical & Cultural Context

Black cohosh rhizome has been used medicinally by Indigenous North American peoples, including the Cherokee, Iroquois, and Algonquin nations, for centuries to treat gynecological conditions including menstrual irregularities, labor facilitation, and menopausal complaints, with the plant known by names such as 'squawroot' and 'black snakeroot.' European settlers adopted these uses by the 18th century, and black cohosh became a prominent constituent of patent medicines in the 19th century United States, notably in Lydia E. Pinkham's Vegetable Compound, a widely marketed women's tonic. The German Commission E formally approved black cohosh extract for menopausal symptoms in 1989, driving modern phytopharmaceutical research that led to the isolation and characterization of actein as a key bioactive triterpene glycoside alongside 23-epi-26-deoxyactein and cimicifugoside. The genus was reclassified from Cimicifuga to Actaea in the early 2000s based on molecular phylogenetic data, reflecting the compound's botanical nomenclature evolution from 'cimicifugoside' frameworks to 'actein'-centered nomenclature.

## Synergistic Combinations

Actein has demonstrated in vitro synergistic inhibition of breast cancer cell proliferation when combined with standard chemotherapeutic agents, with the proposed mechanism involving actein-mediated intracellular calcium mobilization and [NF-κB](/ingredients/condition/inflammation) suppression sensitizing cells to cytotoxic drug-induced apoptosis. Within black cohosh extracts, actein is believed to act synergistically with co-occurring triterpene glycosides such as 23-epi-26-deoxyactein and cimicifugoside, as well as phenolic acids like isoferulic acid, collectively producing broader estrogenic modulation and menopausal symptom relief than any single constituent alone. From a phytopharmacological perspective, combining standardized black cohosh extract with St. John's Wort (Hypericum perforatum) has been clinically evaluated for menopausal symptoms (hot flushes plus mood disturbance), representing the most evidence-supported combination stack containing actein-bearing material.

## Frequently Asked Questions

### What is actein and what plant does it come from?

Actein is a cycloartane-type triterpene glycoside (β-D-xylopyranoside) isolated from the rhizome of Actaea racemosa, commonly known as black cohosh, a woodland plant native to eastern North America. It is one of the principal bioactive compounds in black cohosh alongside 23-epi-26-deoxyactein and cimicifugoside, and is responsible in part for the plant's documented anti-proliferative, anti-angiogenic, and menopausal symptom-relieving properties. Actein can be obtained as a purified research compound or consumed indirectly through standardized black cohosh extracts.

### Does actein help with menopause symptoms?

Actein contributes to the menopausal symptom-relieving effects of black cohosh extracts, which have been used traditionally and evaluated in clinical trials for hot flushes, night sweats, and hormonal imbalances; however, no clinical trials have tested isolated actein specifically for these endpoints. Human evidence comes from studies on whole black cohosh extracts (such as isopropanolic extract standardized to 2.5% triterpene glycosides) rather than purified actein, making it impossible to attribute clinical benefit exclusively to this single compound. Black cohosh extracts are typically dosed at 40–80 mg of standardized extract twice daily for menopausal symptoms, with regulatory guidance suggesting use be limited to 6 months.

### What is the evidence for actein's anti-cancer properties?

Preclinical evidence shows actein inhibits murine 4T1 breast cancer cell proliferation with an IC50 of 0.065 μM and reduces tumor growth, lung metastasis, and liver metastasis in mice at oral doses of 10–15 mg/kg for 28 days (n=6/group). Mechanistically, actein suppresses VEGFR1 and Angiopoietin-2 gene expression in tumor tissue, inhibits ERK and JNK phosphorylation in endothelial cells, and modulates NF-κB and Ras/Raf/MEK/ERK pathways. Critically, no human clinical trials exist for actein in cancer, so these findings cannot be applied to clinical practice and should be interpreted strictly as hypothesis-generating preclinical data.

### Is actein safe to take, and are there any side effects?

Safety data for isolated actein in humans is absent, as no human studies have been conducted; at concentrations below 20 μM in cell assays, actein showed no cytotoxicity by MTT and trypan blue methods. In the context of black cohosh supplements containing actein, rare cases of hepatotoxicity have been reported with prolonged use, and regulatory agencies in Germany and elsewhere advise limiting black cohosh use to 6 months and avoiding it in patients with liver disease or hormone-sensitive cancers. Actein-containing products are not recommended during pregnancy due to historical uterotonic use, and potential interactions with CYP3A4-metabolized drugs and hormone therapies warrant medical supervision.

### What is the human equivalent dose of actein based on animal studies?

Using standard allometric body surface area scaling (FDA conversion factor of approximately 12.3 for mouse-to-human), the murine efficacious dose of 10–15 mg/kg/day translates to approximately 0.8–1.2 mg/kg/day in humans, though this conversion has not been validated for actein in any clinical study. Pharmacokinetic data from rats dosed at 35.7 mg/kg orally demonstrated a serum Cmax of 2.4 μg/mL at 6 hours, confirming oral bioavailability, but equivalent human exposure thresholds remain unknown. Until Phase I dose-escalation studies are conducted, no safe or effective human dose for purified actein can be recommended.

### How does actein's anti-angiogenic mechanism work against tumor growth?

Actein suppresses VEGFR1 protein expression in human microvascular endothelial cells in a concentration-dependent manner, with maximal effects observed at 20 μM concentrations. By reducing VEGFR1 expression, actein inhibits the formation of new blood vessels that tumors rely on for nutrient supply and growth support. This anti-angiogenic activity represents a distinct mechanism from actein's direct effects on cancer cell proliferation, potentially offering complementary therapeutic benefits. The suppression of pathological blood vessel formation is particularly relevant for limiting tumor progression and metastasis.

### What is the potency of actein against breast cancer cells in laboratory studies?

Actein demonstrates selective inhibition of 4T1 murine breast cancer cell proliferation with an IC50 (half-maximal inhibitory concentration) of 0.065 μM, indicating potent activity at very low concentrations. This low IC50 value suggests actein can effectively suppress cancer cell growth at relatively modest doses compared to some conventional approaches. The selectivity of actein for cancer cells over normal cells makes it a promising candidate for further research into breast cancer prevention and treatment. However, these results are from laboratory studies and have not yet been confirmed in human clinical trials.

### Should actein supplementation be considered differently for cancer prevention versus other health conditions?

Actein's specific anti-angiogenic and cancer cell-inhibiting properties suggest it may have particular relevance for individuals interested in cancer prevention strategies, distinct from its traditional use for menopausal symptom relief. Because actein's anti-cancer mechanisms involve targeted cellular pathways, its potential benefits may vary significantly depending on cancer type, individual genetics, and overall health status. Anyone considering actein supplementation for cancer-related purposes should consult with an oncologist, as the compound may interact with cancer treatments or have implications for ongoing medical therapies. Current evidence remains primarily laboratory-based, so cancer prevention applications should not replace established medical screening and treatment protocols.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*